-
![PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF](/abs-image/US/2022/03/10/US20220073530A1/abs.jpg.150x150.jpg)
公开(公告)号：US20220073530A1
公开(公告)日：2022-03-10
申请号：US17527717
申请日：2021-11-16
Applicant: AbbVie Inc.
Inventor： Ayman ALLIAN , Jayanthy JAYANTH , Mohamed-Eslam F. MOHAMED , Mathew MULHERN , Fredrik Lars NORDSTROM , Ahmed A. OTHMAN , Michael J. ROZEMA , Lakshmi BHAGAVATULA , Patrick J. MARROUM , Peter T. MAYER , Ahmad Y. SHEIKH , Thomas B. BORCHARDT , Ben KLÜNDER
IPC: C07D487/14 , A61K9/00 , A61K31/4985 , A61K47/12 , A61K47/38
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis), kits, methods of synthesis, and products-by-process.
-
![PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF](/abs-image/US/2020/06/11/US20200181158A1/abs.jpg.150x150.jpg)
公开(公告)号：US20200181158A1
公开(公告)日：2020-06-11
申请号：US16787251
申请日：2020-02-11
Applicant: AbbVie Inc.
Inventor： Ayman ALLIAN , Jayanthy JAYANTH , Ben KLÜNDER , Mohamed-Eslam F. MOHAMED , Ahmed A. OTHMAN , Patrick J. MARROUM , Peter T. MAYER
IPC: C07D487/14 , A61K47/38 , A61K47/12 , A61K31/4985 , A61K9/00
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
-
公开(公告)号：US20170189402A1
公开(公告)日：2017-07-06
申请号：US15246279
申请日：2016-08-24
Applicant: AbbVie Inc.
Inventor： Todd MCDERMOTT , Benjamin M. COLLMAN , Weili E. WANG , Peter T. MAYER , Albert SANTIAGO , Leana O'KEEFFE , John B. MORRIS
IPC: A61K31/513 , A61K9/28 , A61K9/20 , A61K9/24 , A61K31/427
CPC classification number: A61K31/513 , A61K9/146 , A61K9/2013 , A61K9/2027 , A61K9/209 , A61K31/427 , A61K2300/00
Abstract: The present invention features solid dosage forms comprising two or more different active ingredients. In one embodiment, the present invention features a tablet dosage form comprising a first layer and a second layer, wherein the first layer comprises (1) 200 mg lopinavir, (2) ritonavir, (3) a pharmaceutically acceptable hydrophilic polymer, (4) a pharmaceutically acceptable surfactant, and (5) no more than 0.2% by weight of one or more lubricants, and the second layer comprises another therapeutic agent.
-
公开(公告)号：US20160362431A1
公开(公告)日：2016-12-15
申请号：US15216009
申请日：2016-07-21
Applicant: AbbVie, Inc.
Inventor： Benoit CARDINAL-DAVID , Vincent S. CHAN , Kassibla DEMPAH , Brian P. ENRIGHT , Rodger F. HENRY , Raimundo HO , Ye HUANG , Alexander D. HUTERS , Russell C. KLIX , Scott W. KRABBE , Philip R. KYM , Yanbin LAO , Xiaochun LOU , Sean E. MACKEY , Mark A. MATULENKO , Peter T. MAYER , Christopher P. MILLER , James STAMBULI , Eric A. VOIGHT , Zhi WANG , Geoff G. ZHANG , Valentino J. STELLA
IPC: C07F9/09 , A61K31/661 , A61K45/06 , C07F9/06 , A61K31/6615
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
Abstract translation: 本公开内容涉及（a）卡比多巴前药，（b）药物组合和包含卡比多巴前药和/或左旋多巴前药的组合物，和（c）治疗帕金森病和相关病症的方法，包括施用卡比多巴前药和 左旋多巴前药与帕金森病患者。
-
![PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF](/abs-image/US/2022/08/11/US20220251101A1/abs.jpg.150x150.jpg)
公开(公告)号：US20220251101A1
公开(公告)日：2022-08-11
申请号：US17717486
申请日：2022-04-11
Applicant: AbbVie Inc.
Inventor： Ayman ALLIAN , Jayanthy JAYANTH , Mohamed-Eslam F. MOHAMED , Mathew MULHERN , Fredrik Lars NORDSTROM , Ahmed A. OTHMAN , Michael J. ROZEMA , Lakshmi BHAGAVATULA , Patrick J. MARROUM , Peter T. MAYER , Ahmad Y. SHEIKH , Thomas B. BORCHARDT , Ben KLÜNDER
IPC: C07D487/14 , A61K9/00 , A61K31/4985 , A61K47/12 , A61K47/38
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).
-
Patent Agency Ranking
![PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF](/abs-image/US/2020/10/08/US20200317682A1/abs.jpg.150x150.jpg)
公开(公告)号：US20200317682A1
公开(公告)日：2020-10-08
申请号：US16905667
申请日：2020-06-18
Applicant: AbbVie Inc.
Inventor： Ayman ALLIAN , Thomas B. BORCHARDT , Jayanthy JAYANTH , Patrick J. MARROUM , Peter T. MAYER , Mathew M. MULHERN , Fredrik Lars Nordstrom , Ahmad Y. SHEIKH
IPC: C07D487/14 , A61K9/00 , A61K31/4985 , A61K47/12 , A61K47/38
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
-
![PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A]PYRROLO[2,3-E]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF](/abs-image/US/2019/10/17/US20190315761A1/abs.jpg.150x150.jpg)
公开(公告)号：US20190315761A1
公开(公告)日：2019-10-17
申请号：US16453684
申请日：2019-06-26
Applicant: AbbVie Inc.
Inventor： Ayman ALLIAN , Jayanthy JAYANTH , Ben KLÜNDER , Mohamed-Eslam F. MOHAMED , Ahmed A. OTHMAN , Patrick J. MARROUM , Peter T. MAYER
IPC: C07D487/14 , A61K31/4985 , A61K9/00 , A61K47/38 , A61K47/12
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
-
公开(公告)号：US20160106765A1
公开(公告)日：2016-04-21
申请号：US14919418
申请日：2015-10-21
Applicant: AbbVie Inc.
Inventor： Benoit CARDINAL-DAVID , Vincent S. CHAN , Kassibla E. DEMPAH , Brian P. ENRIGHT , Rodger F. HENRY , Raimundo HO , Ye HUANG , Alexander D. HUTERS , Russell C. KLIX , Scott W. KRABBE , Philip R. KYM , Yanbin LAO , Xiaochun LOU , Sean E. MACKEY , Mark A. MATULENKO , Peter T. MAYER , Christopher P. MILLER , James STAMBULI , Eric A. VOIGHT , Zhi WANG , Geoff G. ZHANG , Valentino J. STELLA
IPC: A61K31/661 , C07F9/06
CPC classification number: C07F9/094 , A61K31/661 , A61K31/6615 , A61K45/06 , C07B2200/13 , C07C47/277 , C07C281/02 , C07C309/24 , C07F9/06 , A61K2300/00
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
Abstract translation: 本公开内容涉及（a）卡比多巴前药，（b）药物组合和包含卡比多巴前药和/或左旋多巴前药的组合物，和（c）治疗帕金森病和相关病症的方法，包括施用卡比多巴前药和 左旋多巴前药与帕金森病患者。
-
![PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF](/abs-image/US/2021/11/25/US20210363149A1/abs.jpg.150x150.jpg)
公开(公告)号：US20210363149A1
公开(公告)日：2021-11-25
申请号：US17184194
申请日：2021-02-24
Applicant: AbbVie Inc.
Inventor： Ayman ALLIAN , Jayanthy JAYANTH , Mohamed-Eslam F. MOHAMED , Mathew M. MULHERN , Fredrik Lars NORDSTROM , Ahmed A. OTHMAN , Michael J. ROZEMA , Lakshmi BHAGAVATULA , Patrick J. MARROUM , Peter T. MAYER , Ahmad Y. SHEIKH , Thomas B. BORCHARDT , Ben KLÜNDER
IPC: C07D487/14 , A61K9/00 , A61K31/4985 , A61K47/12 , A61K47/38
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
-
![PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF](/abs-image/US/2021/10/07/US20210309667A1/abs.jpg.150x150.jpg)
公开(公告)号：US20210309667A1
公开(公告)日：2021-10-07
申请号：US17230288
申请日：2021-04-14
Applicant: AbbVie Inc.
Inventor： Ayman ALLIAN , Jayanthy JAYANTH , Mohamed-Eslam F. MOHAMED , Mathew MULHERN , Fredrik Lars NORDSTROM , Ahmed A. OTHMAN , Michael J. ROZEMA , Lakshmi BHAGAVATULA , Patrick J. MARROUM , Peter T. MAYER , Ahmad Y. SHEIKH , Thomas B. BORCHARDT , Ben KLÜNDER
IPC: C07D487/14 , A61K9/00 , A61K31/4985 , A61K47/12 , A61K47/38
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.023 seconds)
